237 related articles for article (PubMed ID: 18473860)
21. Current Status and Perspectives Regarding LNA-Anti-miR Oligonucleotides and microRNA miR-21 Inhibitors as a Potential Therapeutic Option in Treatment of Colorectal Cancer.
Nedaeinia R; Avan A; Ahmadian M; Nia SN; Ranjbar M; Sharifi M; Goli M; Piroozmand A; Nourmohammadi E; Manian M; Ferns GA; Ghayour-Mobarhan M; Salehi R
J Cell Biochem; 2017 Dec; 118(12):4129-4140. PubMed ID: 28401648
[TBL] [Abstract][Full Text] [Related]
22. DNA drug design for cancer therapy.
Cho-Chung YS
Curr Pharm Des; 2005; 11(22):2811-23. PubMed ID: 16101439
[TBL] [Abstract][Full Text] [Related]
23. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
24. Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design.
Braasch DA; Liu Y; Corey DR
Nucleic Acids Res; 2002 Dec; 30(23):5160-7. PubMed ID: 12466540
[TBL] [Abstract][Full Text] [Related]
25. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
Vester B; Wengel J
Biochemistry; 2004 Oct; 43(42):13233-41. PubMed ID: 15491130
[TBL] [Abstract][Full Text] [Related]
26. Perspectives on chemistry and therapeutic applications of Locked Nucleic Acid (LNA).
Kaur H; Babu BR; Maiti S
Chem Rev; 2007 Nov; 107(11):4672-97. PubMed ID: 17944519
[No Abstract] [Full Text] [Related]
27. Locked nucleic acid as a novel class of therapeutic agents.
Veedu RN; Wengel J
RNA Biol; 2009; 6(3):321-3. PubMed ID: 19458498
[TBL] [Abstract][Full Text] [Related]
28. Antisense-based cancer therapeutics: are we there yet?
Rayburn ER; Wang H; Zhang R
Expert Opin Emerg Drugs; 2006 May; 11(2):337-52. PubMed ID: 16634705
[TBL] [Abstract][Full Text] [Related]
29. Antisense oligonucleotides for the treatment of dyslipidaemia.
Visser ME; Witztum JL; Stroes ES; Kastelein JJ
Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
[TBL] [Abstract][Full Text] [Related]
30. Chemical Development of Therapeutic Oligonucleotides.
Lundin KE; Gissberg O; Smith CIE; Zain R
Methods Mol Biol; 2019; 2036():3-16. PubMed ID: 31410788
[TBL] [Abstract][Full Text] [Related]
31. Oligonucleotides and oligonucleotide conjugates: a new approach for cancer treatment.
Da Ros T; Spalluto G; Prato M; Saison-Behmoaras T; Boutorine A; Cacciari B
Curr Med Chem; 2005; 12(1):71-88. PubMed ID: 15638731
[TBL] [Abstract][Full Text] [Related]
32. Liver as a target for oligonucleotide therapeutics.
Sehgal A; Vaishnaw A; Fitzgerald K
J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
[TBL] [Abstract][Full Text] [Related]
33. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
Taniguchi H; Suzuki Y; Imai K; Adachi Y
Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
[TBL] [Abstract][Full Text] [Related]
34. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
35. A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides.
Takata R; Makado G; Kitamura A; Watanabe H; Wada T
RNA Biol; 2016; 13(3):279-89. PubMed ID: 26890856
[TBL] [Abstract][Full Text] [Related]
36. Oligonucleotide delivery: a patent review (2010 - 2013).
Grijalvo S; Aviñó A; Eritja R
Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
[TBL] [Abstract][Full Text] [Related]
37. Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development.
Orum H; Wengel J
Curr Opin Mol Ther; 2001 Jun; 3(3):239-43. PubMed ID: 11497347
[TBL] [Abstract][Full Text] [Related]
38. Locked nucleic acid oligonucleotides: the next generation of antisense agents?
Grünweller A; Hartmann RK
BioDrugs; 2007; 21(4):235-43. PubMed ID: 17628121
[TBL] [Abstract][Full Text] [Related]
39. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity.
Rankin AM; Faller DV; Spanjaard RA
Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043
[TBL] [Abstract][Full Text] [Related]
40. Technology evaluation: MG-98, MethylGene.
Zhang Z
Curr Opin Mol Ther; 2001 Dec; 3(6):599-604. PubMed ID: 11804276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
